Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
In This Article:
CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024.
Leading independent third party proxy advisory firm ISS has recommended that shareholders vote FOR all the proposed resolutions.
The Board of Directors of XORTX recommends that Shareholders vote FOR ALL proposed items
Your vote is important no matter how many shares you hold. Please vote today.
The proxy voting deadline is 10:00 am (Calgary time) on Tuesday, September 10, 2024
Meeting Details
XORTX will hold its meeting on September 12, 2024, at 10:00 am (Calgary Time) at the offices of the Company at 3710 – 33rd Street NW, Calgary.
Please visit the Company’s website complete details and links to all relevant documents ahead of the Meeting at the link below:
Questions & Voting
If you have questions about the meeting matters or require voting assistance please contact XORTX‘s proxy solicitation agent, Laurel Hill Advisory Group at:
North American Toll Free: 1-877-452-7184 (1-416-304-0211 outside North America)
Email: assistance@laurelhill.com
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.
| For more information, please contact: |
|
|
|
|
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com or +1 403 455 7727 | nick@alpineequityadv.com or +1 617 901 0785 |
|
|
|
| Kim Golodetz, LHA Investor Relations |
|
| kgolodetz@lhai.com or +1 212 838 3777 |
|
Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.